KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EPS (Basic) (2016 - 2025)

Pacira BioSciences has reported EPS (Basic) over the past 16 years, most recently at $0.04 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.04 for Q4 2025, down 88.57% from a year ago — trailing twelve months through Dec 2025 was $0.15 (up 106.94% YoY), and the annual figure for FY2025 was $0.16, up 107.44%.
  • EPS (Basic) for Q4 2025 was $0.04 at Pacira BioSciences, down from $0.12 in the prior quarter.
  • Over the last five years, EPS (Basic) for PCRX hit a ceiling of $0.56 in Q2 2023 and a floor of -$3.11 in Q3 2024.
  • Median EPS (Basic) over the past 5 years was $0.17 (2022), compared with a mean of $0.01.
  • Biggest five-year swings in EPS (Basic): soared 1250.0% in 2023 and later plummeted 1452.17% in 2024.
  • Pacira BioSciences' EPS (Basic) stood at -$0.12 in 2021, then crashed by 83.33% to -$0.22 in 2022, then skyrocketed by 345.45% to $0.54 in 2023, then tumbled by 35.19% to $0.35 in 2024, then plummeted by 88.57% to $0.04 in 2025.
  • The last three reported values for EPS (Basic) were $0.04 (Q4 2025), $0.12 (Q3 2025), and -$0.11 (Q2 2025) per Business Quant data.